Applied Molecular Transport Inc.

    Applied Molecular Transport Inc.

    NNASDAQ:AMTI
    0.26
    USD
    0.00
    (0.00%)
    No data availableFinancial data will appear here once available

    Capital Structure

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Working Capital

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Growth Rates

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Revenue

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Earnings Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Quarterly Dividends Per Share

    FRC

    •

    in mil. unless spec.
    No data availableFinancial data will appear here once available

    Company Description

    Address
    Similar Companies
    Business

    Company News

    • Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

    • APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

    • Applied Molecular Transport Reports Third Quarter 2023 Financial Results

    • APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

    • Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

    • Applied Molecular Transport Reports Second Quarter 2023 Financial Results

    • What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock

    • Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?

    • Applied Molecular Transport to Present at Upcoming November Investor Conferences

    • Zephyr AI Announces Additions to the Board of Directors

    • INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

    • INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm

    • Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

    • VMware Advances Its Anywhere Workspace Platform To Enable Intelligent, Proactive Security for All Employee Devices

    • Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs

    • Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference

    • Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

    • Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference

    • Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021

    • Applied Molecular Transport Announces Upcoming Investor Events in September and October